Melanoma | Patterns of Care: Optimizing the Current Management of Melanoma with BRAF Mutation in the Real World - a podcast by Dr Neil Love
from 2021-01-14T23:00
::
::
Featuring a roundtable discussion with Drs Adil Daud, Michael Postow, Hussein Tawbi and Jeffrey S Weber on the following topics:
- Metastatic Disease
- Introduction
- Case: A woman in her early 50s with Stage IV melanoma and a solitary brain metastasis
- Case: A man in his early 20s with metastatic melanoma with a BRAF mutation and CNS metastases
- Case: A woman in her mid-80s with metastatic melanoma with a BRAF mutation who received encorafenib/binimetinib
- Case: A man in his early 60s with widespread metastatic melanoma
- Case: A man in his mid-80s with metastatic melanoma with a BRAF mutation and a PD-L1 CPS (combined positive score) of 10%
- Available evidence and ongoing research with the combination of BRAF/MEK inhibitors and immunotherapy for advanced melanoma with a BRAF mutation
- Assessment of PD-L1 level in deciding on first-line therapy for patients with metastatic melanoma
- First-line therapy options for younger patients with metastatic melanoma with BRAF mutations
- Case: A woman in her early 50s with melanoma with a BRAF mutation and brain metastases
- Case: A man in his mid-70s with metastatic melanoma with a BRAF mutation
- Similarities and differences among BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) used in the treatment of metastatic melanoma with a BRAF mutation
- Effects of the COVID-19 pandemic on the clinical care of patients with melanoma
- Case: A man in his mid-20s with newly diagnosed metastatic melanoma with a BRAF V600E mutation
- Case: A woman in her late 40s with metastatic melanoma with a BRAF mutation
- Thresholds for dose reduction and delay with dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib
- Adjuvant Systemic Therapy
- Case: A man in his early 70s with Stage IIIC melanoma and diabetes
- Case: A woman in her early 50s with melanoma with a high tumor mutation burden
- Case: A woman in her mid-60s with Stage IIIC melanoma with a BRAF V600E mutation
- Use of encorafenib/binimetinib or vemurafenib/cobimetinib as adjuvant therapy
- Potential contraindications for immune checkpoint inhibitors (eg, prior autoimmune disease, transplant)
- Case: A woman in her early 50s with localized melanoma and a BRAF V600E mutation
- Case: A woman in her early 70s with localized melanoma and a BRAF V600E mutation; duration of adjuvant therapy with BRAF/MEK combinations
- Case: An otherwise healthy man in his early 30s with localized melanoma and a BRAF V600K mutation
CME information and select publications
Further episodes of Research To Practice | Oncology Videos
Further podcasts by Dr Neil Love
Website of Dr Neil Love